Full-Time
Project Manager 2 and Project Manager 1
Fortrea
10,001+ employees
Global CRO providing Phase I-IV trials
No salary listed
United Kingdom
Hybrid
Hybrid role; some on-site days in the United Kingdom.
Bachelor's, Master's, PhD
 Business & Strategy (1) |
|---|
Get referred to Fortrea
See people who can refer or advise you
- For Project Manager II, extensive clinical research experience within a CRO or biopharmaceutical environment, including at least 2 years of full project management accountability on domestic, regional and or international clinical studies.
- For Project Manager I, at least 4 years of clinical research experience in a pharmaceutical company/CRO, including a minimum 1-2 years of experience working in a project management environment.
- Phase 1 and Phase Ib experience: Familiarity with early-phase trials in healthy volunteers and patients and their fast-paced environment is ideal, but international PM experience in Ph II-III will also be welcomed.
- Financial acumen: study budget management skills, with experience in forecasting, revenue recognition and change order development and negotiation.
- Leadership: proven ability to inspire and manage globally dispersed teams and vendors, ensuring cross-functional collaboration and achieving core project milestones. Ability to work on multiple studies at any one time.
- Risk management: expertise in critical path analysis and the development of effective risk mitigation plans.
- Client relations: a probing ability to build client trust, resolve complex challenges and influence decisions.
- BID presentation expertise.
- Education/Qualifications: University/college life science degree from an appropriately accredited institution.
- Lead the end-to-end delivery of assigned Healthy Volunteers and Patient Clinical Pharmacology projects independently or under the direction of a Senior Project Lead, overseeing complex, high-value studies across regional/global, cross-functional teams.
- Act as the primary point of contact for sponsor project teams, managing expectations, driving communication, and building long-term client relationships.
- Own project scope, timelines, and budgets, proactively managing change, financial performance, and delivery against contractual commitments.
- Apply your project leadership expertise to anticipate, identify, and mitigate risks, managing critical paths to ensure key milestones and performance metrics remain aligned with both client and Fortrea objectives.
- Provide senior leadership within a matrix project environment, guiding and mentoring project team members while resolving issues and escalations at pace.
- Ensure quality, compliance, and audit readiness, maintaining oversight of TMFs, CTMS activities, project training, and adherence to SOPs and ICH/GCP standards.
- Contribute to business growth and operational excellence, supporting bid defence activities, strategic client relationships, KPI oversight, and process improvement initiatives.
- Master’s or other advanced degree.
- PMP certification.
Fortrea is a global contract research organization that provides clinical development services for the life sciences industry. It offers full service, functional service, and hybrid outsourcing models across Phase I–IV trials, clinical pharmacology, and consulting, serving biotech, biopharma, medical devices, and diagnostics. Its work is delivered through a network of investigators and specialized teams in approximately 100 countries, supporting trial design, execution, data management, and regulatory compliance. Fortrea’s approach combines its legacy experience from Covance and Labcorp with a pureplay CRO model to deliver fit-for-purpose solutions and agile project delivery. This positions it to manage trials across more than 20 therapeutic areas with scientific rigor and operational excellence. The company aims to bring predictability to clinical trial execution and help clients turn research ideas into real-world outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
Durham, North Carolina
Founded
2023
Get referred to Fortrea
See people who can refer or advise you
Simplify's Take
What believers are saying
- Fortrea raised 2026 revenue guidance to $2.62 billion-$2.69 billion on July 29, 2026.
- Book-to-bill stayed above 1.0x for four straight quarters, supporting backlog conversion.
- Q2 2026 operating margin improved to 2.2%, showing cost cuts and discipline are working.
What critics are saying
- Jason Knoblauch is on paid leave after Delaware Chancery restraints; finance leadership remains unstable.
- Q2 2026 revenue still fell 4.5%, signaling weak demand and pricing pressure.
- Large-pharma FSP renewals already forced pricing concessions; another renewal cycle can crush 2027 margins.
What makes Fortrea unique
- Fortrea’s April 7, 2026 FIT platform embeds AI into clinical trial operations.
- Fortrea spans phase I-IV trials across roughly 100 countries with deep investigator-site reach.
- Fortrea’s 2023 Labcorp spinout preserved a focused CRO model for pharma, biotech, and devices.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Paid Vacation
Growth & Insights and Company News
6 month growth
↑ 27%1 year growth
↑ 27%2 year growth
↑ 27%Fortrea, a contract research organisation spun off from Labcorp in 2023, reported Q2 revenues of $678.2 million, down 4.5% year-on-year but exceeding analyst expectations by 4.7%. The company helps pharmaceutical, biotech, and medical device companies develop products through clinical trials and support services. Chief executive officer Anshul Thakral said the results reflected continued progress against the company's strategy and disciplined execution. The quarter saw Fortrea beat earnings per share estimates, with full-year revenue guidance surpassing analyst expectations. Among the eight drug development inputs and services stocks tracked, revenues collectively beat consensus estimates by 4.1%. Despite posting the slowest revenue growth in the group, the sector's share prices rose 12.6% on average. Fortrea's stock fell 5.7% following the results and currently trades at $19.52.
Fortrea Holdings reported second-quarter revenue of $678.2 million, exceeding analyst estimates by 4.7% despite a 4.5% year-on-year decline. The clinical research company's adjusted earnings per share of $0.23 beat consensus estimates by 27.2%. The company raised its full-year revenue guidance to $2.66 billion at the midpoint, up 2.1% from previous guidance and 1.8% above analyst expectations. Full-year EBITDA guidance of $212.5 million also surpassed estimates. Operating margin improved significantly to 2.2%, compared to negative 46.5% in the same quarter last year. CEO Anshul Thakral said the results reflect continued progress against the company's strategy. However, analysts project revenue to remain flat over the next 12 months, suggesting limited near-term growth prospects.
Fortrea, a global contract research organisation, has appointed Jason Knoblauch as chief financial officer, effective 6 July 2026. He will succeed Jill McConnell, who is stepping down after helping establish Fortrea as an independent CRO. Knoblauch joins from Clario, where he served as CFO. He previously held the CFO position at Curia and various financial leadership roles at Pharmaceutical Product Development, including interim CFO and helping lead the company to a successful IPO in 2020. Earlier, he worked in PricewaterhouseCoopers' Transaction Services practice. The company reiterated its 2026 financial guidance, targeting revenues between $2,550 million and $2,650 million, with adjusted EBITDA of $190 million to $220 million.
Why Fortrea (FTRE) stock is trading up today. Anthony lee /. June 24, 2026 What happened? Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 4.6% in the morning session after Barclays raised its price target on the company's shares to $18 from $16, while maintaining an Equal Weight rating. The adjustment by analyst Luke Sergott was part of a second-quarter preview for the life science and diagnostic tools space. According to the analyst's research note, tools are "gaining favor among healthcare subsectors," a trend that is likely to continue into the earnings reporting season. Barclays expects companies in the sector to report quarterly results that are in-line with or slightly better than expectations. What is the market telling us. Fortrea's shares are extremely volatile and have had 64 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 8 months ago when the stock gained 25.3% on the news that the company reported third-quarter financial results that showed stronger-than-expected revenue and an improved outlook for the full year. For the third quarter, Fortrea announced revenues of $701.3 million, which surpassed analyst estimates. However, its adjusted earnings of $0.12 per share fell short of projections. Despite the mixed bottom-line results, investors appeared to focus on the company's future prospects. Fortrea raised its revenue guidance for the full year to a midpoint of $2.73 billion, up from its previous forecast of $2.65 billion. This improved outlook, along with the strong quarterly sales, signaled confidence in the company's growth, outweighing the earnings miss. Fortrea is up 2.9% since the beginning of the year, and at $17.30 per share, it is trading close to its 52-week high of $18.40 from January 2026. Investors who bought $1,000 worth of Fortrea's shares at the IPO in June 2023 would now be looking at an investment worth $574.58. WHILE YOU'RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You've probably never heard of it. This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
Fortrea exceeded Wall Street expectations in its first quarter results, posting revenue of $636.5 million versus estimates of $627.5 million and adjusted earnings per share of $0.16 against estimates of $0.05. The clinical research services company's adjusted EBITDA reached $47 million, beating analyst estimates of $34.61 million. CEO Anshul Thakral attributed the performance to improved commercial execution and a rebound in biotech client activity, with the company achieving a higher book-to-bill ratio for the third consecutive quarter. CFO Jill McConnell highlighted operational discipline and cost-optimisation initiatives as key drivers of margin expansion. Fortrea reaffirmed its full-year revenue guidance of $2.6 billion at the midpoint and raised EBITDA guidance to $205 million, above analyst estimates of $201.8 million. The company's market capitalisation stands at $1.42 billion.